Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma

被引:18
作者
Boulin, Mathieu [1 ,2 ]
Adam, Heloise [1 ]
Guiu, Boris [2 ,3 ]
Aho, Ludwig Serge [4 ]
Cercueil, Jean-Pierre [2 ,3 ]
Di Martino, Cyrille [4 ]
Fagnoni, Philippe [1 ,2 ]
Minello, Anne [2 ,5 ]
Jouve, Jean Louis [2 ,5 ]
Hillon, Patrick [2 ,5 ]
Bedenne, Laurent [2 ,5 ]
Lepage, Come [2 ,5 ]
机构
[1] CHU Univ Hosp, Dept Pharm, F-21000 Dijon, France
[2] Univ Burgundy, F-21079 Dijon, France
[3] CHU Univ Hosp, Dept Radiol, F-21000 Dijon, France
[4] Georges Francois Leclerc Anticanc Ctr, Dept Pharm, F-21079 Dijon, France
[5] CHU Univ Hosp, Dept Hepatogastroenterol, F-21079 Dijon, France
关键词
Hepatocellular carcinoma; Toxicity; Transarterial chemoembolisation; LIPIODOL CHEMOEMBOLIZATION; COHORT; TRIAL; MODEL;
D O I
10.1016/j.dld.2013.12.012
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Transarterial chemoembolisation (TACE) is an effective treatment for unresectable hepatocellular carcinoma (HCC), but can cause severe toxicity. Aim: To identify predictive factors of severe TACE-related toxicity in patients with unresectable HCC. Methods: All HCC patients who underwent TACE at the Dijon University Hospital between 2008 and 2011 were included in this retrospective study. Severe TACE-related toxicity was defined as the occurrence of any adverse event grade >= 4, or any adverse event that caused a prolongation of hospitalisation of >8 days, or any additional hospitalisation within 1 month after TACE. Factors predicting toxicity were identified using a logistic regression model. The robustness of the final model was confirmed using bootstrapping (500 replications). Results: 124 patients were included, median age was 67 years and 90% were male; 22 patients (18%) experienced severe TACE-related toxicity. Factors that independently predicted severe TACE-related toxicity in multivariate analysis were total tumour size (OR, 1.15 cm(-1); 95% CI, 1.04-1.26; p = 0.01), and high serum AST levels (OR, 1.10 per 10 IU/l; 95% CI, 1.01-1.21; p = 0.04). The results were confirmed by bootstrapping. Conclusions: Total tumour size and high serum AST levels were predictive factors of severe TACE-related toxicity in this hospital-based series of patients with unresectable HCC. (C) 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:358 / 362
页数:5
相关论文
共 50 条
  • [31] Prognostic factors associated with survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolisation: an Australian multicenter cohort study
    Mishra, Gauri
    Dev, Anouk
    Paul, Eldho
    Kemp, William
    Majeed, Ammar
    Lubel, John
    Bell, Sally
    Gow, Paul
    Nicoll, Amanda
    Sood, Siddharth
    Thompson, Alex
    Ryan, Marno
    Roberts, Stuart K.
    HEPATOMA RESEARCH, 2021, 7
  • [32] Combined transarterial chemoembolization and tislelizumab for patients with unresectable hepatocellular carcinoma
    Tan, Bin-Bin
    Fu, Ying
    Shao, Ming-Hua
    Chen, Hai-Lei
    Liu, Ping
    Fan, Chao
    Zhang, Hui
    WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2024, 16 (09):
  • [33] A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation
    Inaba, Yoshitaka
    Kanai, Fumihiko
    Aramaki, Takeshi
    Yamamoto, Takanobu
    Tanaka, Toshihiro
    Yamakado, Koichiro
    Kaneko, Shuichi
    Kudo, Masatoshi
    Imanaka, Kazuho
    Kora, Shinichi
    Nishida, Norifumi
    Kawai, Nobuyuki
    Seki, Hiroshi
    Matsui, Osamu
    Arioka, Hitoshi
    Arai, Yasuaki
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (13) : 2832 - 2840
  • [34] Comparison Between Radial and Femoral Artery Access for Transarterial Chemoembolisation in Patients With Hepatocellular Carcinoma
    Hedjoudje, Mohamed
    Barat, Maxime
    Dohan, Anthony
    Lucas, Alexandre
    Dautry, Raphael
    Coriat, Romain
    Marchese, Ugo
    Pol, Stanislas
    Parlati, Lucia
    Soyer, Philippe
    CANADIAN ASSOCIATION OF RADIOLOGISTS JOURNAL-JOURNAL DE L ASSOCIATION CANADIENNE DES RADIOLOGISTES, 2024, 75 (01): : 178 - 186
  • [35] Rare pulmonary and cerebral complications after transarterial chemoembolisation for hepatocellular carcinoma: A case report
    Zhao, Hua
    Wang, Hui-Qin
    Fan, Qing-Qiu
    Chen, Xing-Xian
    Lou, Jian-Ying
    WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (41) : 6425 - 6427
  • [36] SURVIVAL AND TOXICITY AFTER TREATMENT WITH SORAFENIB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA
    Rebegea, Laura
    Bujenita, Mariana
    Ivan, Iuliana
    Craescu, Mihaela
    Firescu, Dorel
    Romila, Aurelia
    Dumitru, Mihaela
    Serban, Cristina
    ACTA MEDICA MEDITERRANEA, 2019, 35 (04): : 2023 - 2028
  • [38] Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
    Han, Yue
    Cao, Guang
    Sun, Bin
    Wang, Jian
    Yan, Dong
    Xu, Haifeng
    Shi, Qinsheng
    Liu, Zechuan
    Zhi, Weihua
    Xu, Liang
    Liu, Bojun
    Zou, Yinghua
    BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [39] Transarterial chemoembolization for unresectable hepatocellular carcinoma: A comparison of the efficacy and safety of 2 embolic agents
    Chen, Shiguang
    Yu, Wenchang
    Zhang, Kongzhi
    Liu, Weifu
    Chen, Qizhong
    MEDICINE, 2018, 97 (21)
  • [40] Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma
    Wan, Xuying
    Zhai, Xiaofeng
    Yan, Zhenlin
    Yang, Pinghua
    Li, Jun
    Wu, Dong
    Wang, Kui
    Xia, Yong
    Shen, Feng
    ONCOTARGET, 2016, 7 (50) : 83806 - 83816